Nutex Health Inc. announced restated fourth quarter and fiscal year 2024 financial results.
Major balance sheet adjustments were made, resulting in a net increase to liabilities and a decrease in equity.
The restatements had no material effect on key metrics such as revenue, liquidity, and operating cash flow.
Total Revenue Increase
Total revenue increased by 93.8% from $247.6 million in 2023 to $479.9 million in 2024.
Net Income Improvement
Net income attributable to Nutex Health Inc. improved from a loss of $45.8 million in 2023 to $52.1 million in 2024.
Adjusted EBITDA Growth
Adjusted EBITDA increased significantly by 1046.1% from $10.8 million in 2023 to $124.1 million in 2024.
Stock-Based Compensation
Significant stock-based compensation expenses were reported, impacting operating income and net income.
- The restated financial results show substantial growth in total revenue and net income for Nutex Health.
- Adjusted EBITDA experienced a remarkable increase, reflecting improved financial performance in 2024.
- Stock-based compensation expenses had a notable impact on operating income, indicating investments in human capital.
- The restated figures demonstrate the company's commitment to transparency and accuracy in financial reporting.
Nutex Health's restated financial results for 2024 reflect significant improvements in revenue, net income, and EBITDA, showcasing the company's financial strength and strategic growth.